MED-EL Announces the Acquisition of Non-Implantable Bone Conduction Technology from Otorix

  • The new solution can be used for treating children younger than five years, allowing for timely acquirement of hearing and language skills
  • New system will expand MED-EL’s existing wide range of hearing solutions

Austria, 18th July 2016 – MED-EL has announced that it has acquired the technology for the Adjoin bone conduction hearing system from the Swedish medical device company Otorix. The system is a novel non-surgical solution for conductive hearing loss* that will enable MED-EL to reach more candidates while expanding its portfolio of hearing solutions.

The system comprises two parts: an adhesive adapter and audio processor which are worn together discretely behind the ear. It is an excellent option for people with conductive hearing loss who are unsuitable for, or not wishing to undergo, bone conduction implant surgery. All system components are easy-to- use and maintain and transmit sound to the inner ear with no applied skin  pressure.

Patrik Westerkull, founder and CEO of Otorix, said: “It was my ambition to take the bone conduction field further. With the Adjoin technology we finally have a non-implantable bone conduction solution that does not require pressure on the skin for effective and reliable sound transmission, while also providing excellent comfort and great aesthetics. I look forward to working with MED-EL on bringing this fantastic product to the market.”

The new product will be the first non-implantable hearing solution produced by MED-EL which already offers the widest range of implantable hearing solutions. This includes the world´s first active bone conduction implant – the BONEBRIDGE. The new combination of technology and expertise in this sector will support MED-EL’s growth in key markets.

Dr. Ingeborg Hochmair, CEO of MED-EL, said: “This exciting technology will be an important supplement to our range of implantable solutions including the BONEBRIDGE. It fills the unmet need for a pressureless, non-implantable bone conduction solution and firmly enforces MED-EL’s mission to overcome hearing loss as a barrier to communication and quality of life.”

First clinical trial results have been extremely successful and development of the product continues with an expected launch date in 2017.

*Conductive hearing loss causes include congenital ear malformations (such as aural microtia and atresia) and a large range of middle ear disorders.


**Please note, Thumbay Group, Gulf Medical University, and HEALTH magazine are not liable nor responsible for the facts, figures, and overall content of the press releases on our portal.

Related Articles